Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

Journal of Infectious Diseases

Volumn 203, Issue 5, 2011, Pages 610-619

  Goepfert, Paul A ^a   Elizaga, Marnie L ^b   Sato, Alicia ^b   Qin, Li ^b   Cardinali, Massimo ^c   Hay, Christine M ^e   Hural, John ^b   DeRosa, Stephen C ^b   DeFawe, Olivier D ^b   Tomaras, Georgia D ^f   Montefiori, David C ^f   Xu, Yongxian ^g   Lai, Lilin ^h   Kalams, Spyros A ⁱ   Baden, Lindsey R ^j   Frey, Sharon E ^k   Blattner, William A ^d   Wyatt, Linda S ^c   Moss, Bernard ^c   Robinson, Harriet L ^g  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g Research and Development   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; ENVELOPE PROTEIN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NEUTRALIZING ANTIBODY; PLACEBO;

ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPNEA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; LOW DRUG DOSE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VIRUS LIKE AGENT;

ADOLESCENT; ADULT; AIDS VACCINES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PLACEBOS; UNITED STATES; VACCINES, DNA; VACCINIA VIRUS; YOUNG ADULT;

EID: 79751487021     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq105     Document Type: Article

References (35)

1. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65.
2. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-905.
3. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
5. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74. (Pubitemid 32289126)
6. Amara RR, Villinger F, Staprans SI, et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002; 76: 7625-31. (Pubitemid 34760986)
7. Ellenberger D, Otten RA, Li B, et al. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology 2006; 352:216-25. (Pubitemid 44160714)
8. Smith JM, Amara RR, Campbell D, et al. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses 2004; 20:1335-47. (Pubitemid 40065929)
9. Smith JM, Amara RR, McClure HM, et al. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in macaques. AIDS Res Hum Retroviruses 2004; 20:654-65. (Pubitemid 38813664)
10. Wyatt LS, Earl PL, Liu JY, et al. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component. AIDS Res Hum Retroviruses 2004; 20:645-53. (Pubitemid 38813663)
11. Wyatt LS, Earl PL, Vogt J, et al. Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 2008; 26:486-93.
12. Wyatt LS, Belyakov IM, Earl PL, Berzofsky JA, Moss B. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 2008; 372:260-72. (Pubitemid 351273747)
13. Bull M, Lee D, Stucky J, et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 2007; 322:57-69. (Pubitemid 46560582)
14. Horton H, Thomas EP, Stucky JA, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007; 323:39-54. (Pubitemid 46722712)
15. Li F, Malhotra U, Gilbert PB, et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 2006; 24:6893-904. (Pubitemid 46107181)
16. Perfetto SP, Chattopadhyay PK, Lamoreaux L, et al. Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J Immunol Methods 2006; 313:199-208.
17. Barouch DH, O'Brien KL, Simmons NL, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010; 16:319-23.
18. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82:12449-63.
19. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-25. (Pubitemid 41098552)
20. Lai L, Vodros D, Kozlowski PA, et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007; 369:153-67. (Pubitemid 350030833)
21. Zhao J, Lai L, Amara RR, et al. Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol 2009; 83:4102-11.
22. Mulligan MJ, Russell ND, Celum C, et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses 2006; 22:678-83. (Pubitemid 44061404)
23. Ourmanov I, Brown CR, Moss B, et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol 2000; 74:2740-51. (Pubitemid 30117585)
24. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348-57.
25. Hanke T, Goonetilleke N, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 2007; 88:1-12. (Pubitemid 46085108)
26. Sandstrom E, Nilsson C, Hejdeman B, et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008; 198:1482-90.
27. Harari A, Bart PA, Stohr W, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008; 205:63-77. (Pubitemid 351185716)
28. McCormack S, Stohr W, Barber T, et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008; 26:3162-74.
29. Goepfert PA, Horton H, McElrath MJ, et al. High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 2005; 192:1249-59. (Pubitemid 41368426)
30. Hel Z, Nacsa J, Tsai WP, et al. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology 2002; 304:125-34. (Pubitemid 36062839)
31. Pal R, Venzon D, Letvin NL, et al. ALVAC-SIV-Gag-Pol-Env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002; 76:292-302. (Pubitemid 33139014)
32. + T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006; 80:3732-42.
33. Russell ND, Graham BS, Keefer MC, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a Phase 3 correlates trial. J Acquir Immune Defic Syndr 2007; 44:203-12. (Pubitemid 46292224)
34. Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293-9.
35. Liu J, O'Brien KL, Lynch DM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87-91.